ADPT
NASDAQ · Life Sciences Tools & Services
Adaptive Biotechnologies
$14.27
+0.17 (+1.21%)
Financial Highlights (FY 2026)
Revenue
300.78M
Net Income
-64,616,860
Gross Margin
74.2%
Profit Margin
-21.5%
Rev Growth
+14.3%
D/E Ratio
0.60
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 74.2% | 74.2% | 29.3% | 29.3% |
| Operating Margin | -20.6% | -18.6% | 12.2% | 13.6% |
| Profit Margin | -21.5% | -20.4% | 14.0% | 10.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 300.78M | 263.05M | 1.18B | 1.15B |
| Gross Profit | 223.30M | 195.29M | 346.79M | 336.38M |
| Operating Income | -62,020,112 | -48,817,649 | 144.00M | 155.55M |
| Net Income | -64,616,860 | -50,861,617 | 166.04M | 120.97M |
| Gross Margin | 74.2% | 74.2% | 29.3% | 29.3% |
| Operating Margin | -20.6% | -18.6% | 12.2% | 13.6% |
| Profit Margin | -21.5% | -20.4% | 14.0% | 10.5% |
| Rev Growth | +14.3% | +14.3% | +9.0% | -7.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 440.68M | 440.68M | 456.20M | 455.55M |
| Total Equity | 734.84M | 734.84M | 1.50B | 1.38B |
| D/E Ratio | 0.60 | 0.60 | 0.30 | 0.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -49,377,034 | -41,025,172 | 190.10M | 191.59M |
| Free Cash Flow | — | — | 135.00M | 109.51M |